Rocket Pharma director granted RSUs and options
Rocket Pharmaceuticals director Peter Fong received equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rocket Pharmaceuticals director Peter Fong received equity awards as part of his compensation. He was granted 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received a stock option to purchase 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and will expire on June 18, 2036. Following the restricted stock unit grant, his direct common stock holdings reported in this filing total 76,195 shares.
Insider Trade Summary
Grant/Award: 87,722 shares
Grant/Award
2 txns
Insider
Fong Peter
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 64,860 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,862 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 64,860 contracts (Direct);
Common Stock — 76,195 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
- F2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Key Figures
RSU grant size: 22,862 RSUs
Option grant size: 64,860 options
Option exercise price: $3.35/share
+3 more
6 metrics
RSU grant size
22,862 RSUs
Restricted stock units vesting June 18, 2027
Option grant size
64,860 options
Stock option covering common shares
Option exercise price
$3.35/share
Exercise price for 64,860-share option
Option expiration
June 18, 2036
Expiration date of stock option grant
RSU vesting date
June 18, 2027
Full vesting date for 22,862 RSUs
Common shares after grant
76,195 shares
Direct Rocket Pharmaceuticals common stock holdings
Key Terms
restricted stock units, RSUs, Stock Option (Right to Buy), exercise price, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $3.35 per share."
exercise price financial
"This option represents a right to purchase a total of 64,860 shares ... with an exercise price of $3.35 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested and exercisable financial
"All of which will become fully vested and exercisable on June 18, 2027."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Peter Fong report at Rocket Pharmaceuticals (RCKT)?
Peter Fong reported receiving equity compensation awards, not open-market trades. He was granted restricted stock units and a stock option, both tied to Rocket Pharmaceuticals common stock, with future vesting and exercisability dates rather than immediate cash transactions.
What are the details of Peter Fong’s stock option grant at Rocket Pharmaceuticals (RCKT)?
He received a stock option covering 64,860 shares of Rocket Pharmaceuticals common stock at an exercise price of $3.35 per share. The option becomes fully vested and exercisable on June 18, 2027 and is scheduled to expire on June 18, 2036 if not exercised earlier.
When do Peter Fong’s Rocket Pharmaceuticals (RCKT) RSUs and options vest?
Both the restricted stock units and the stock option grants vest in full on June 18, 2027. At that point, the RSUs convert one-for-one into common shares, and the option becomes fully exercisable at the stated $3.35 per share exercise price.
Are Peter Fong’s Rocket Pharmaceuticals (RCKT) transactions open-market buys or compensation awards?
The reported transactions are compensation-related awards, not open-market purchases or sales. The Form 4 shows grants of restricted stock units and a stock option, both coded as acquisitions under a grant or award transaction type rather than discretionary market trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates